Oct 22, 2019 9:28am EDT Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate
Oct 10, 2019 4:05pm EDT Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
Aug 12, 2019 7:47am EDT Sonnet BioTherapeutics Announces Acquisition Agreement with Relief Therapeutics Holding SA for Atexakin Alpha (Interleukin-6)
Jul 17, 2018 10:26am EDT Sonnet BioTherapeutics announces successful completion of Immuno-Oncology Discovery Program and Initiation of CMC Development of Platform Assets
Sep 25, 2017 11:36am EDT Sonnet Biotherapeutics to present data on bispecific platform candidates at AACR and SITC Annual Meetings
